0.15Open0.15Pre Close0 Volume14 Open Interest0.50Strike Price0.00Turnover249.45%IV12.28%PremiumOct 18, 2024Expiry Date0.10Intrinsic Value100Multiplier16DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.5655Delta1.8908Gamma2.67Leverage Ratio-0.0026Theta-0.0001Rho-1.51Eff Leverage0.0003Vega
FibroGen Stock Discussion
hope you can perform again 💪💪💪
FibroGen Inc - Study Did Not Meet Primary Endpoint
FibroGen, Inc. (NASDAQ:FGEN) recently announced a milestone in its oncology pipeline. The U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for FG-3165, a novel galectin-9 (Gal9) targeted monoc...
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
FibroGen (NASDAQ: FGEN) announced FDA clearance for its Investigational New Drug (IND) application for FG-3165, a monoclonal antibody targeting galectin-9 (Gal9) for treating solid tumors. FG-3165 has shown anti-tumor activity and improved survival in preclinical models and exhibited excellent tol...
FibroGen Announces Clinical Trial Supply Agreement With Regeneron Pharmaceuticals to Evaluate Fibrogen’s Immuno-Oncology Assets, FG-3165 (Anti-Galectin 9) and FG-3175 (Anti-Ccr8), in Combination With Libtayo® in Upcoming Clinical Trials
No comment yet